Purpose Sotatercept, an activin signalling inhibitor approved in March 2024 for pulmonary arterial hypertension (PAH), ...
Amendments to the International Health Regulations (IHR) effective September 19, 2025, aim to protect global health security.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback